Rossari Biotech's Q2 FY 2025-26 Quarterly Results

Result Summary

• Rossari Biotech Ltd reported a 7.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.8%.
• Its expenses for the quarter were up by 7.8% QoQ and 19.3% YoY.
• The net profit increased 9.8% QoQ and increased 4.4% YoY.
• The earnings per share (EPS) of Rossari Biotech Ltd stood at 6.65 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Rossari Biotech Ltd is a prominent player in the specialty chemicals industry. The company is known for its extensive portfolio of products catering to diverse sectors such as textiles, animal health and nutrition, and home and personal care. Established as a leader in sustainable solutions, Rossari Biotech has consistently focused on innovation and customer-centric approaches. While specific recent developments are not detailed here, the company's strategic expansions and product developments have typically been geared towards enhancing its competitive edge in the market.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Rossari Biotech Ltd reported a total income of ₹587.71 crores. This marks a 7.9% increase from the previous quarter (Q1FY26), where the total income was ₹544.92 crores. Compared to the same quarter in the previous year (Q2FY25), the total income rose by 17.8% from ₹499.07 crores. This year-over-year growth highlights an upward trajectory in the company's revenue generation capabilities over the past year.

Profitability

Rossari Biotech Ltd's profit before tax for Q2FY26 was ₹49.20 crores, showing a 7.9% rise quarter-over-quarter from ₹45.58 crores in Q1FY26. When compared year-over-year, there was a 2.9% increase from ₹47.82 crores in Q2FY25. The tax expense for Q2FY26 was ₹12.80 crores, slightly up by 2.4% from the previous quarter and nearly unchanged year-over-year with a 0.2% increase. Consequently, the profit after tax in Q2FY26 stood at ₹36.88 crores, reflecting a 9.8% growth from the preceding quarter and a 4.4% increase from the same quarter last year. Earnings per share (EPS) also saw an increase, registering ₹6.65 in Q2FY26, up by 9.7% QoQ and 4.2% YoY.

Operating Metrics

The total expenses for Rossari Biotech Ltd in Q2FY26 amounted to ₹538.50 crores, which represents a 7.8% increase from the prior quarter and a 19.3% rise year-over-year from Q2FY25. This indicates a consistent increase in operating expenses, which aligns with the company's growth in revenue. The company's ability to manage its expenses while simultaneously driving revenue growth is reflected in the stable profit margins observed over the quarters. The financial data suggests an efficient handling of operational costs in relation to income.